Melanoma News and Research

Latest Melanoma News and Research

Scientists identify dangerous 'two-faced' protein crucial to breast cancer spread and growth

Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.

17 Nov 2008

Intervention program boosts survival in breast cancer patients

A new study provides the best evidence to date that a psychological intervention program designed for breast cancer patients not only improves their health - it actually increases their chance of survival.

17 Nov 2008

Blood exosomes shown to contain tumor-specific genetic information for brain cancer

Tiny vesicles called exosomes released into the bloodstream from aggressive brain tumors contain genetic signatures that may help guide future diagnosis and treatment of this deadly disease.

17 Nov 2008

Prime Ministers and Presidents must be more open about their health status

Anyone who runs for Prime Minister or President should have an independent health examination to ensure their ability to govern, argues a doctor on bmj.com today.

12 Nov 2008

Differences between benign and cancerous moles

Research into a cancer that is on the rise in the UK is to be presented at the University of Leicester.

11 Nov 2008

Novel leukemia therapy shows promise for high-risk patients

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

4 Nov 2008

Liver transplant recipients face increased risks of developing cancer

A new Canadian study comparing cancer rates of liver transplant patients to those of the general population has found that transplant recipients face increased risks of developing cancer, especially non-Hodgkin's lymphoma and colorectal cancer.

4 Nov 2008

Substance tackles skin cancer with two-pronged attack

By playing it safe and using a two-pronged attack, a novel designer molecule fights malignant melanoma. It was created and tested by an international team of researchers led by the University of Bonn.

2 Nov 2008

Nanoparticles target multiple cancer genes, shrink tumors more effectively

Nanoparticles filled with small interfering RNA (siRNA) molecules targeting two genes that trigger melanoma have shown that they can inhibit the development of melanoma, the most dangerous type of skin cancer.

27 Oct 2008

Educational literature can influence young women's use of indoor tanning

A new study indicates that educational literature can influence young women's use of indoor tanning, not by raising their fear of skin cancer but by changing their attitudes about indoor tanning and promoting healthier alternatives for changing appearance.

23 Oct 2008

Sun-damaged skin responds well to laser treatment

Researchers at the University of Michigan Health System Department of Dermatology have found scientific evidence that the appearance of sun-damaged skin may be improved by treatment with a topical product that increases the skin's sensitivity to light, followed by laser therapy.

20 Oct 2008

Just how common is skin cancer in Australia?

A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.

14 Oct 2008

OncoGenex achieves key regulatory milestone for lead product candidate

OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).

13 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Social class dictates cancer risk

Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy. A detailed analysis of the incidence of these four different kinds of cancer, carried out on more than 300,000 English cancer patients and published today in the open access journal BMC Cancer, describes the effects of socioeconomic group, region and age.

25 Sep 2008

Sun exposure may have an anti-melanoma effect

Italian researchers have found a link between vitamin D and the risk of developing a melanoma and they say that individuals with certain variants in a vitamin D-related gene, called BsmI, may be at an increased risk of developing melanoma.

22 Sep 2008

No such thing as a 'safe' suntan

Three review papers from leading researchers in the fields of cell biology, dermatology and epidemiology have looked closely at the effects on skin of UV radiation, including that from indoor tanning beds.

18 Sep 2008

Variations in cyclin D1 gene increase susceptibility to malignant melanoma

People who carry a particular genetic variant are at significantly increased risk of developing malignant melanoma, new research shows.

15 Sep 2008

Inovio Biomedical achieves 75% complete response rate in preclinical testing of DNA-based cancer vaccine using its electroporation DNA delivery system

Inovio Biomedical Corporation announced today that it achieved positive results from its proprietary research and development program for DNA-based cancer vaccines delivered using the company's electroporation-based DNA delivery technology.

15 Sep 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008